TABLE 2.

Prospective studies on HHV-6 reactivation after SOT

Transplant typeDetection methodbSamplecNo. of patientsIncidence of active HHV-6 infection (%)Observed diseaseeHHV-6 variantReference
HeartPCRPBMC210No disease298
KidneyPCRPBMC107Not givendNo diseaseNot determined320
KidneyqPCRPBMC5223No diseaseNot determined205
KidneyVI, serologyPBMC6555NoneNot determined455
Kidney and/or liverVI, serologyPBMC3231None (unless concomitant HCMV infection)Not determined162
Kidney and/or pancreasPCR, serologyUrine, serum3050FeverNot determined335
LiverIHCLiver tissue, PBMC32Not givenAcute liver failureNot determined155
LiverIHCPBMC3429HCMV diseaseNot determined232
LiverqPCRPBMC20028Opportunistic infections, HCMV disease, acute graft rejectionNot determined171
LiverqPCR, serologyPBMC339HCMV diseaseNot determined281
LiverqPCRPBMC8854HCMV diseaseNot determined173
LiverPCR, VI, serologyPlasma4749FeverB452
LiverVIPBMC8039CNS disease, fungal infectionsNot determined340
LiverSerology, IHCPBMC5122Graft dysfunctionB233
LiverqPCRPBMC6032Graft rejectionNot determined150
LiverSerologySerum24724HCMV diseaseNot determined108
LiverPCRPBMC46Not givenNone10% A, 90% B357
LiveraqPCRPBMC6654Increased severity of HCV-related fibrosis or hepatitisNot determined172
LiveraVIPBMC5141Increased severity of HCV-related fibrosisNot determined364
Liver heart/lungVI, PCRPBMC, BALF3027Higher mortality rate, fungal infectionsB192
  • a Study population restricted to hepatitis C virus-positive patients undergoing liver transplantation.

  • b qPCR, quantitative PCR; VI, virus isolation; IHC, immunohistochemistry.

  • c BALF, bronchoalveolar lavage fluid.

  • d Unclear whether PCR was able to discriminate active from latent infection.

  • e HCV, hepatitis C virus.